产品
编 号：F715525
分子式：C16H12F5N3O2S
分子量：405.34
分子式：C16H12F5N3O2S
分子量：405.34
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 251442-94-1
产品详情
生物活性：
Enflicoxib (E 6087) is a nonsteroidal anti-inflammatory compound that selectively inhibits cyclooxygenase-2 (COX-2).?Enflicoxib does not inhibit cyclooxygenase-1 (COX-1). E-6087 shows anti-inflammatory, analgesic and antipyretic activities in animal models.
体内研究：
E-6132, one of Enflicoxib (E-6087) metabolites, also inhibits COX-2.?After single oral administration of 5 mg/kg of E-6087 to rats, plasma concentrations of Enflicoxib at peak time are higher than those of E-6132, suggesting that activity is mainly due to Enflicoxib.Enflicoxib (E-6087) is characterized by a long elimination half-life (20-35 h), a low plasma clearance (0.10-0.22 L/h/kg) and a relatively large volume of distribution (2-6 L/kg) in rats and dogs after single oral and intravenous doses. Enflicoxib and E-6132 (a pharmacologically active metabolite) show different pharmacokinetics. The higher percentage of Enflicoxib at early times suggests that Enflicoxib is the main compound responsible for in vivo activity, although E-6132 would contribute to the activity at later times.Animal Model:Male and female Wistar rats (250 g)
Dosage:5 mg/kg
Administration:Administered by gastric gavage (10 mL/kg); a single oral dose
Result:Plasma concentrations of E-6087 at peak time are higher than those of E-6132.
Enflicoxib (E 6087) is a nonsteroidal anti-inflammatory compound that selectively inhibits cyclooxygenase-2 (COX-2).?Enflicoxib does not inhibit cyclooxygenase-1 (COX-1). E-6087 shows anti-inflammatory, analgesic and antipyretic activities in animal models.
体内研究：
E-6132, one of Enflicoxib (E-6087) metabolites, also inhibits COX-2.?After single oral administration of 5 mg/kg of E-6087 to rats, plasma concentrations of Enflicoxib at peak time are higher than those of E-6132, suggesting that activity is mainly due to Enflicoxib.Enflicoxib (E-6087) is characterized by a long elimination half-life (20-35 h), a low plasma clearance (0.10-0.22 L/h/kg) and a relatively large volume of distribution (2-6 L/kg) in rats and dogs after single oral and intravenous doses. Enflicoxib and E-6132 (a pharmacologically active metabolite) show different pharmacokinetics. The higher percentage of Enflicoxib at early times suggests that Enflicoxib is the main compound responsible for in vivo activity, although E-6132 would contribute to the activity at later times.Animal Model:Male and female Wistar rats (250 g)
Dosage:5 mg/kg
Administration:Administered by gastric gavage (10 mL/kg); a single oral dose
Result:Plasma concentrations of E-6087 at peak time are higher than those of E-6132.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备